Related Experiment Video
Updated: Jan 12, 2026
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.5K
Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction
Aravinthan Vignarajah1, San Kim1, Moath Albliwi1
1Department of Medicine Cleveland Clinic Fairview Hospital Cleveland OH USA.
Journal of the American Heart Association
|November 6, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve survival and heart failure outcomes in cancer patients with cancer therapy-related cardiac dysfunction (CTRCD). This study suggests GLP-1 RA use is linked to better outcomes for CTRCD patients on heart failure therapy.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cancer therapies can cause cardiac dysfunction (CTRCD).
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show cardioprotective effects.
- The role of GLP-1 RAs in CTRCD is not well-established.
Purpose of the Study:
- To investigate the impact of GLP-1 RA use on outcomes in patients with CTRCD.
- To evaluate the association between GLP-1 RA therapy and mortality, heart failure exacerbations, and hospitalizations in CTRCD patients.
Main Methods:
- Retrospective cohort study using the TriNetX research network.
- Included adults with cancer history, antineoplastic therapy, and CTRCD (2012-2023).
- Propensity score matching (1:1) compared GLP-1 RA users and nonusers on guideline-directed medical therapy for heart failure over 1 year.
Main Results:
- GLP-1 RA users (n=837) showed significantly lower all-cause mortality (HR 0.57), acute heart failure exacerbations (HR 0.69), and all-cause hospitalizations (HR 0.83) compared to nonusers.
- Reductions in atrial fibrillation/flutter and ventricular tachycardia were observed but not statistically significant.
- The cohort included 4982 patients with CTRCD, with 837 receiving GLP-1 RA therapy.
Conclusions:
- GLP-1 RA use in patients with CTRCD on guideline-directed medical therapy may be associated with improved 1-year survival.
- GLP-1 RA therapy appears linked to better heart failure-related outcomes in this patient population.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511
01:23Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
01:15G Protein-coupled Receptors
16.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K